Neuroscience
From today's Boston Globe:~
(Reminder: "PML" is the abbreviation for "progressive multifocal leukoencephalopathy.")~
Note: The NEJM material is accessible, online "early release" material, found on the journal's content homepage, includes the PML case studies, two editorials, and correspondence. The set will appear in the printed version of the journal on the 28th of July.
BRIEF REPORT: G. Van Assche et al. Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
BRIEF REPORT: B.K. Kleinschmidt-DeMasters & K.L. Tyler. Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
BRIEF REPORT: A. Langer-Gould et al. Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
EDITORIAL: J.R. Berger & I.J. Koralnik. Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
EDITORIAL: J.M. Drazen. Patients at Risk
CORRESPONDENCE: Natalizumab and Progressive Multifocal Leukoencephalopathy
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Fda: Progressive Multifocal Leukoencephalopathy (pml) And Tysabri (natalizumab)
From the FDA: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri For Immediate Release: January 20, 2012 [snip]"Today, the U.S. Food and Drug Administration allowed marketing of the first test to...
- Fda: Updated Info On Tysabri (natalizumab)
From the FDA: Information on Natalizumab (marketed as Tysabri) Updated Information: [9/2009] The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri. Tysabri was approved by the FDA for the...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
- Business World: Tysabri (natalizumab) And Biogen Idec
From today's Boston Globe: Biogen Idec's top lawyer quits amid investigation By Jeffrey Krasner The Boston Globe March 10, 2005 Thomas J. Bucknum, Biogen Idec's longtime top lawyer, resigned suddenly yesterday amid an inquiry by the Securities...
Neuroscience
Business World: Biogen Idec, Elan, & Tysabri (Natalizumab)
From today's Boston Globe:
Biogen MS drug gets lift from reports[ ... Read the full article ... ]
Medical journal suggests Tysabri may make a return
By Jeffrey Krasner
The Boston Globe
10 June 2005
Biogen Idec Inc.'s drug Tysabri might be safely given to multiple sclerosis patients if they are carefully monitored for an often fatal brain disease, according to articles in The New England Journal of Medicine.
Three patients taking the medication have contracted the disease, known as PML, and a fourth case is suspected. But some doctors writing in the journal speculated that monitoring might make it possible to discontinue treatment with Tysabri -- known generically as natalizumab -- and treat patients in time to prevent PML from developing into a life-threatening illness.
(Reminder: "PML" is the abbreviation for "progressive multifocal leukoencephalopathy.")
Note: The NEJM material is accessible, online "early release" material, found on the journal's content homepage, includes the PML case studies, two editorials, and correspondence. The set will appear in the printed version of the journal on the 28th of July.
BRIEF REPORT: G. Van Assche et al. Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
BRIEF REPORT: B.K. Kleinschmidt-DeMasters & K.L. Tyler. Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
BRIEF REPORT: A. Langer-Gould et al. Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
EDITORIAL: J.R. Berger & I.J. Koralnik. Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
EDITORIAL: J.M. Drazen. Patients at Risk
CORRESPONDENCE: Natalizumab and Progressive Multifocal Leukoencephalopathy
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Fda: Progressive Multifocal Leukoencephalopathy (pml) And Tysabri (natalizumab)
From the FDA: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri For Immediate Release: January 20, 2012 [snip]"Today, the U.S. Food and Drug Administration allowed marketing of the first test to...
- Fda: Updated Info On Tysabri (natalizumab)
From the FDA: Information on Natalizumab (marketed as Tysabri) Updated Information: [9/2009] The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri. Tysabri was approved by the FDA for the...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
- Business World: Tysabri (natalizumab) And Biogen Idec
From today's Boston Globe: Biogen Idec's top lawyer quits amid investigation By Jeffrey Krasner The Boston Globe March 10, 2005 Thomas J. Bucknum, Biogen Idec's longtime top lawyer, resigned suddenly yesterday amid an inquiry by the Securities...